- Home
- WRLD vs ARVN Comparison
WRLD vs ARVN Comparison
Compare WRLD & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRLD | ARVN |
|---|---|---|
| Founded | 1962 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.6M | 781.0M |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WRLD | ARVN |
|---|---|---|
| Price | $138.62 | $12.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $15.71 |
| AVG Volume (30 Days) | 113.4K | ★ 668.1K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $564,841,465.00 | $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $104.99 | $5.90 |
| 52 Week High | $185.48 | $14.22 |
Technical Indicators
Market Signals| Indicator | WRLD | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 39.85 |
| Support Level | $138.35 | $11.07 |
| Resistance Level | $140.69 | $12.62 |
| Average True Range (ATR) | 7.29 | 0.65 |
| MACD | -0.20 | -0.17 |
| Stochastic Oscillator | 53.93 | 7.02 |
Price Performance
Historical ComparisonAbout WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.